AnalystBook Research · Company Intelligence

Edwards Lifesciences Corp

EWNYSE

Built from Edwards Lifesciences Corp's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Edwards grew structural-heart revenue and cash flow, but reported earnings reset after the Critical Care sale gain.

The read at a glance✓ Audited against SEC data
  • GrowthRevenue +11.5% to $6.07BOK
  • ProfitabilityNet income -74.3% to $1.07BWatch
  • Cash qualityFCF +360.5% to $1.34BOK
  • MarginsGross -145 bps; operating margin -451 bpsWatch
  • CapitalBuybacks -22.9%; capex +3.1%Note
  • Balance sheetDebt flat; equity +3.4%OK
  • AccountingAltman safe; no Beneish flagOK
  • Insiders0 buys / 36 sellsWatch

Business

Edwards Lifesciences is a structural-heart medical device company centered on transcatheter and surgical valve therapies. TAVR is the core franchise at $4.49B of FY2025 revenue, supported by TMTT, Surgical Structural Heart, global direct sales, field clinical specialists, and manufacturing in the United States, Singapore, Costa Rica, and Ireland.

Where the revenue comes from

Fiscal 2025, as Edwards Lifesciences Corp reports it. History and quarterly detail are in the app.

  • United States$3.5B
  • Europe$1.5B
  • Rest of World$652.3M
  • Japan$354.7M

Leadership changes

From Edwards Lifesciences Corp's own filings, the day they're filed.

  • Theodora Mistras · President · appointmenteff. 2026-05-29
  • Larry L. Wood · President · departureeff. 2025-09-01
  • Surgical Structural Heart · President · departureeff. 2025-09-01

Latest filings

  • 8-K · Company announcement2026-08-28
  • 10-Q · Quarterly report2026-08-04
  • 8-K · Company announcement2026-07-23
  • 8-K · Company announcement2026-05-08
  • 10-Q · Quarterly report2026-05-06
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Edwards Lifesciences Corp, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.